WW INTERNATIONAL Business Summary

WW International, Inc. (WW) operates a multi-channel weight management ecosystem primarily driven by a recurring subscription model across two core segments: Behavioral and Clinical. The Behavioral segment generates revenue through digital app-based tools and in-person workshops, while the high-growth Clinical segment (WeightWatchers Clinic) provides medically supervised access to GLP-1 medications integrated with behavioral support. Additional revenue streams include the sale of branded nutritional products and the licensing of intellectual property for consumer goods. In a market increasingly disrupted by pharmaceutical weight-loss solutions, WW has pivoted from a traditional dieting brand to a technology-enabled "weight health" platform. It competes directly with Nutrisystem, Jenny Craig, and The Beachbody Company (BODI), positioning itself as a science-backed hybrid that bridges the gap between clinical medical intervention and long-term behavioral modification. Originally founded in 1963 by Jean Nidetch, the company is currently led by President and CEO Tara Comonte, who assumed the role in February 2025 following her tenure as CFO of Shake Shack and CEO of TMRW Life Sciences. The executive team includes Chief Technology Officer Helene Causse, Chief Financial Officer Felicia DellaFortuna, and Chief Experience Officer Julie Rice, the co-founder of SoulCycle. Clinical strategy is directed by Chief Medical Officer Dr. Kim Boyd, a veteran of One Medical and Calibrate, while Uta Knablein serves as Chief Product Officer. Following a 2025 financial restructuring, the board is chaired by turnaround specialist Eugene Davis and includes notable members such as Mike Mason, formerly of Eli Lilly. While long-time director Oprah Winfrey exited the board in 2024 to eliminate conflicts of interest regarding GLP-1 advocacy, the company maintains significant institutional backing from investors including Aristeia Capital and Carronade Capital.